Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...
The Manila Times1d
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an ...
Zymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...
Bogalusa Mayor Tyrin Truong hires high-profile attorney after facing drug, solicitation of prostitution charges
High-profile attorney Billy Gibbens confirmed to WDSU that he is now representing Bogalusa Mayor Tyrin Truongin in the case.
CURE2d
First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
Targeted Oncology5d
FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer
The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.
Medscape15d
New Bifunctional Drug Shows Sustained Effect in Alopecia Areata
In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways produced impressive improvements in hair regrowth during and after therapy.
The Manila Times14h
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
January 2025 - Cingulate completed its final FDA-required study, a food effect study utilizing a single 50-mg dose of ...
Healio9d
Two-drug regimen active in advanced endometrial cancer
A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...
CURE22h
FDA Approves Cabometyx for Some Neuroendocrine Tumors
The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
Nature12d
Drug safety articles from across Nature Portfolio
FLuID enables privacy-preserving knowledge sharing in drug discovery using knowledge distillation. The results show that the approach expands applicability domains and fosters collaboration across ...